News Sentiment

BIO-B sentiment intelligence

Bio-Rad Laboratories Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 50 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Medical Devices Read-through group
Latest close 298.50 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

79/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+0.7% over one week, -1.9% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Abbott Laboratories stock trades steadily as diagnostics and medical devices support earnings

Market Reaction

Balanced read

48/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 79/100 classification
One-week reaction 0.7% Price digesting
Trend fit Trend inactive -1.9% over four weeks
Fair value -1.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 2
Neutral 46
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
MarketBeat 11
Stock Titan 7
simplywall.st 4
StockStory 3
ad-hoc-news.de 2
TradingView 1
Finviz 1

Event Lens

What the news is about

Classified themes
Earnings 28
Market update 15
Analyst action 3
Deals and strategy 2
Guidance 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-50 of 50
MarketBeat Direct company coverage

Hound Partners LLC Has $29.15 Million Stake in Bio-Rad Laboratories, Inc. $BIO

Hound Partners LLC significantly reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 42.9% in the third quarter, now holding 103,963 shares valued at $29.15 million. This represents about 3.7% of Hound's portfolio. Despite mixed analyst sentiment with a "Hold" rating an

Tone
Neutral 50/100
Event
Analyst action
Published
17 Mar 2026 07:10
Source
MarketBeat
MarketBeat Direct company coverage

Bio-Rad Laboratories, Inc. $BIO Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) during Q3, purchasing an additional 26,119 shares, bringing their total to 65,069 shares valued at $18.25 million. This move is part of a broader trend of institutional investors modifying t

Tone
Neutral 50/100
Event
Deals and strategy
Published
12 Mar 2026 18:53
Source
MarketBeat
MarketBeat Direct company coverage

Capital Research Global Investors Makes New Investment in Bio-Rad Laboratories, Inc. $BIO

Capital Research Global Investors has made a significant new investment in Bio-Rad Laboratories, purchasing 418,355 shares valued at approximately $117.3 million, representing about 1.55% ownership. This move comes as Bio-Rad reported Q4 EPS of $2.51, slightly missing estimates,

Tone
Neutral 50/100
Event
Earnings
Published
12 Mar 2026 13:09
Source
MarketBeat
MarketBeat Direct company coverage

10,425 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Magnetar Financial LLC

Magnetar Financial LLC recently acquired 10,425 shares of Bio-Rad Laboratories (NYSE:BIO) valued at approximately $2.923 million, contributing to institutional investors owning about 65.24% of the stock. Bio-Rad Laboratories reported mixed financial results, missing EPS estimates

Tone
Neutral 50/100
Event
Earnings
Published
12 Mar 2026 10:52
Source
MarketBeat
MarketBeat Direct company coverage

Perbak Capital Partners LLP Purchases 5,423 Shares of Bio-Rad Laboratories, Inc. $BIO

Perbak Capital Partners LLP significantly increased its stake in Bio-Rad Laboratories (NYSE: BIO) by 171.7% in the third quarter of 2026, acquiring 5,423 additional shares. The firm now holds 8,582 shares valued at $2.406 million, making it a substantial holding within their port

Tone
Neutral 50/100
Event
Earnings
Published
12 Mar 2026 10:10
Source
MarketBeat
MarketBeat Direct company coverage

TD Asset Management Inc Purchases 7,386 Shares of Bio-Rad Laboratories, Inc. $BIO

TD Asset Management Inc. significantly increased its stake in Bio-Rad Laboratories (NYSE:BIO) by 461.0% in the third quarter, acquiring an additional 7,386 shares to hold a total of 8,988 shares valued at approximately $2.52 million. Despite this increased institutional interest,

Tone
Neutral 50/100
Event
Earnings
Published
05 Mar 2026 15:52
Source
MarketBeat
MarketBeat Direct company coverage

Roubaix Capital LLC Buys Shares of 8,112 Bio-Rad Laboratories, Inc. $BIO

Roubaix Capital LLC initiated a new position in Bio-Rad Laboratories (NYSE:BIO), acquiring 8,112 shares valued at approximately $2.275 million during the third quarter. The company reported slightly lower-than-expected quarterly earnings and revenue, with EPS of $2.51 against an

Tone
Neutral 50/100
Event
Earnings
Published
03 Mar 2026 14:52
Source
MarketBeat
MarketBeat Direct company coverage

CenterBook Partners LP Has $2.56 Million Holdings in Bio-Rad Laboratories, Inc. $BIO

CenterBook Partners LP reduced its stake in Bio-Rad Laboratories, Inc. by 36.4% in the third quarter, holding 9,129 shares valued at $2.56 million. Despite this, other institutions like Royal Bank of Canada and Goldman Sachs increased their positions, with institutional investors

Tone
Neutral 50/100
Event
Earnings
Published
24 Feb 2026 16:52
Source
MarketBeat
Stock Titan Direct company coverage

Sartorius 2025 results summarized in Bio-Rad (NYSE: BIO) update

Bio-Rad Laboratories, Inc. (NYSE: BIO) has provided an update on its investment in Sartorius AG, sharing Sartorius's full-year 2025 financial figures which were disclosed on February 16, 2026. The update, filed as a Form 8-K, details Sartorius’ sales revenue, gross profit, EBIT,

Tone
Neutral 50/100
Event
Earnings
Published
23 Feb 2026 13:52
Source
Stock Titan
Stock Traders Daily Direct company coverage

(BIO) Movement Within Algorithmic Entry Frameworks

This article provides an algorithmic analysis of Bio-rad Laboratories Inc. Class A (NYSE: BIO), highlighting weak near and mid-term sentiment but a positive long-term outlook. It details three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timef

Tone
Neutral 50/100
Event
Guidance
Published
23 Feb 2026 12:36
Source
Stock Traders Daily
MarketBeat Direct company coverage

Bio-Rad Laboratories (NYSE:BIO.B) Shares Pass Below 200-Day Moving Average - Time to Sell?

Bio-Rad Laboratories (NYSE:BIO.B) shares have fallen below their 200-day moving average, trading at $261.83, which is below the $289.87 average, signaling a potential bearish technical trend. Despite this short-term weakness, the company's fundamentals remain strong, with robust

Tone
Neutral 50/100
Event
Market update
Published
21 Feb 2026 12:51
Source
MarketBeat
TipRanks Direct company coverage

Bio-Rad Updates Investors on Sartorius Strategic Investment Metrics

Bio-Rad Laboratories (BIO) recently informed investors about selected 2025 financial metrics from its strategic investment in Sartorius AG. Sartorius reported €3.54 billion in sales revenue and €542.6 million in EBIT for 2025, providing transparency on the financial health of thi

Tone
Neutral 50/100
Event
Earnings
Published
20 Feb 2026 18:51
Source
TipRanks
Sahm Direct company coverage

Bio Rad Laboratories Q3 Loss Of US$12.70 EPS Tests Recovery Narrative For BIO Stock

Bio-Rad Laboratories (BIO) reported a Q3 FY 2025 basic EPS loss of US$12.70 and US$653 million in revenue, presenting a mixed picture against its volatile financial history. The company's trailing 12-month net loss is US$675.9 million, with analysts forecasting a return to profit

Tone
Neutral 50/100
Event
Earnings
Published
16 Feb 2026 13:52
Source
Sahm
MarketBeat Direct company coverage

Bio-Rad Laboratories (NYSE:BIO.B) Posts Quarterly Earnings Results

Bio-Rad Laboratories (NYSE:BIO.B) recently announced its quarterly earnings, reporting $2.51 EPS. Despite a negative net margin of 26.43%, the company achieved a positive return on equity of 4.19%. Shares remained flat at $295.05 on minimal trading volume, indicating strong liqui

Tone
Neutral 50/100
Event
Earnings
Published
13 Feb 2026 00:27
Source
MarketBeat